Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence.
J Clin Hypertens (Greenwich). 2009;11:512-519. (c)2009 Wiley Periodicals, Inc.Cardiovascular disease accounts for the majority of deaths in patients with type 2 diabetes mellitus. Lifestyle interventions aimed at weight loss and increased physical activity and therapy with antidiabetic drugs have proven effective in reducing the risk of new-onset diabetes in high-risk individuals. Substantial evidence also suggests that drugs that inhibit the renin-angiotensin system, namely angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers, also prolong the time to onset of clinical diabetes. An open question is whether delay of new-onset diabetes with antidiabetic or antihypertensive agents reduces cardiovascular morbidity and mortality. A large ongoing study is investigating whether therapy with an oral antidiabetic drug or an angiotensin II receptor blocker reduces the incidence of new-onset diabetes and cardiovascular events in high-risk patients.
Giles
Thomas D
TD
Heart and Vascular Institute, Tulane University School of Medicine, New Orleans, LA, USA. tgiles1@tulane.edu
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008019:Life Style
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents